Why the study?
TAVI superiority over surgery is maintained only if a femoral approach is possible, prompting an analysis of changes before and after introducing percutaneous transfemoral implantation.
Does the introduction of a routine percutaneous transfemoral approach improve 12-month survival and reduce hospital stay in patients undergoing TAVI?
Does the introduction of a routine percutaneous transfemoral approach improve 12-month survival and reduce hospital stay in patients undergoing TAVI?
The transition to a fully percutaneous transfemoral approach for TAVI is associated with reduced 12-month mortality and shorter hospital stays compared to routine surgical cut-down and transapical approaches.
Answers are grounded in this paper and cite their sources.
May inform femoral-first TAVI strategies in high-risk AS; leaves open generalizability of survival and complication rates.
Background: Transcatheter aortic valve implantation (TAVI) was proved to be a preferred method of severe aortic stenosis treatment in patients with medium and high surgical risk. However, that significant superiority over surgery is maintained only if femoral approach is possible. 1 Aim: We analyzed changes of approach to TAVI implantation before and after the introduction of percutaneous transfemoral implantation, together with data on 12-months survival, complications and hospital stay.
No takes yet. Share an insight, caveat, or question.
Hadžibegović et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: